Monoclonal antibody isolation and characterization for COVID-19 Effort

到目前为止，我们已经从SARS-CoV-2恢复期供者身上分离出了100多株SARS-CoV-2特异性单抗，并在体外鉴定了它们的功能。这些分离和鉴定的单抗中有超过25个对SARS-CoV-2具有中和作用，其中一些还能够中和多种变种的关注(VOC)。其中五种抗体特别令人感兴趣，因为它们能够有效中和SARS-CoV-2、多种VOCs，在某些情况下还能中和SARS1。我们还在分离和鉴定具有泛冠状病毒中和活性的单抗，包括中和中东呼吸综合征冠状病毒(MERS-CoV)。 我们建立了稳定表达hACE2和TMPRSS2a的细胞系，作为SARS-CoV-2假病毒中和试验的靶细胞，并优化和验证了该细胞系，用于体外mAb和人供体血清样本的中和活性的重复性评价。

To date, we have isolated more than 100 SARS-CoV-2-specific monoclonal antibodies (mAbs) from SARS-CoV-2 convalescent donors and characterized their functionality in vitro. More than 25 of these mAbs isolated and characterized were neutralizing against SARS-CoV-2 with several also able to neutralize multiple Variants of Concern (VOC). Five of these antibodies are of particular interest owing to their ability to potently neutralize SARS-CoV-2, multiple VOCs and, in some instances, SARS1. We are also isolating and characterizing mAbs with pan-coronavirus neutralizing activity, including neutralization of Middle East respiratory syndrome coronavirus (MERS-CoV). We have generated a stable cell line co-expressing hACE2 and TMPRSS2a for use as target cells in the SARS-CoV-2 pseudovirus neutralization assay, and optimized and validated this cell one for reproducible evaluation of neutralizing activity by mAb and human donor serum samples in vitro.